MedPath

Effectiveness of Erector Spinae Plane Block for Percutaneous Arthrodesis of Spinal Fractures

Not Applicable
Recruiting
Conditions
SPINAL Fracture
Pain, Postoperative
Interventions
Procedure: ESPB with saline 0,9%
Procedure: Erector spinae plane block with naropeine [3,75 mg/mL]
Registration Number
NCT06200298
Lead Sponsor
University Hospital, Lille
Brief Summary

Spinal fracture surgery is a common surgery. Post-operative pain has been reduced by the advent of so-called minimally invasive techniques. The immediate post-operative pain, however, remains relatively high, mainly because of muscle pain following the trauma.

The erector spinae plane block (ESPB) is a loco-regional anesthesia technique first described in 2016.

A retrospective cohort study showed an improvement in post-operative analgesia of percutaneous osteosynthesis spinal surgery through a reduction in 24-hour morphine use.

In order to prove and confirm the effectiveness of this technique, we will conduct a double-blind randomized controlled study.

The objective will be to demonstrate the analgesic effectiveness of the technique by reducing morphine consumption in post-operative. The expected reduction in morphine consumption is set at 30%, based on the clinical experience developed in our practice.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
86
Inclusion Criteria
  1. Patients with percutaneous arthrodesis spine surgery for fracture
  2. Insured persons
  3. Age 18 years
  4. Being able to receive informed information
  5. Have agreed to participate in writing
Exclusion Criteria
  1. Minor patient
  2. Patient refusal
  3. Pregnancy
  4. Lack of social security coverage
  5. Under guardianship or curatorship
  6. Inability to express consent
  7. History of spinal surgery
  8. Unable to use morphine PCA
  9. Contraindication to the use of local morphines and/or anesthetics
  10. Contraindication to Loco-Regional Anesthesia
  11. Long-term opioid patient (Level II and Level III analgesics)
  12. Patient with preoperative neuropathic pain (score greater than or equal to 4 on the DN4 questionnaire or taking anti-epileptic or anti-depressant treatments for neuropathic pain)

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Control group : ESPB with saline 0,9%ESPB with saline 0,9%-
Erector spinae plane block with naropeine [3,75 mg/mL]Erector spinae plane block with naropeine [3,75 mg/mL]Experimental group: Erector spinae plane block with naropeine \[3,75 mg/mL\]
Primary Outcome Measures
NameTimeMethod
Morphine consumption for the first postoperative 24 hoursduring the first 24H after the procedure

Morphine consumption for the first postoperative 24 hours(mg)

Secondary Outcome Measures
NameTimeMethod
Evolution of postoperative painEvery 3 hours during the first 24 hours

Pain evaluation by numerical scale between 0 (none pain) and 10 (worst pain ever)

Evolution of postoperative morphine consumption 6 hoursPost-operative morphic consumption (mg) at 6 hours

Post-operative morphic consumption (mg)

Evolution of postoperative morphine consumption 12 hourPost-operative morphic consumption (mg) at 12 hours

Post-operative morphic consumption (mg)

Evolution of postoperative morphine consumption 1 hourPost-operative morphic consumption (mg) at postoperative 1 hour

Post-operative morphic consumption (mg)

Duration of stay in postanesthesia care unit (PACU)when two consecutives Aldrete scores at 10 occure

Time (minutes) in PACU ; exit criteria = two consecutives Aldrete scores at 10

intraoperative morphine consumptionduring the procedure

Post-operative morphic consumption (mg)

Evolution of postoperative morphine consumption 3 hoursPost-operative morphic consumption (mg) at 3 hours

Post-operative morphic consumption (mg)

Evolution of postoperative morphine consumption 9 hoursPost-operative morphic consumption (mg) at 9 hours

Post-operative morphic consumption (mg)

Trial Locations

Locations (1)

Hôpital Roger Salengro

🇫🇷

Lille, France

© Copyright 2025. All Rights Reserved by MedPath